Not a good buy right now: the primary trend is bearish (SMA_200 > SMA_20 > SMA_5) and fundamentals just deteriorated sharply.
Price is sitting right on/just below key support (S1 ~1.152) with next support at ~1.052; downside risk remains if support fails.
Oversold conditions (RSI_6 ~21.9) can produce a short bounce, but there is no Intellectia buy signal today to justify an impatient entry.
With no news catalysts, neutral insider/hedge fund activity, and very weak latest-quarter growth, the risk/reward is not attractive for buying immediately.
Technical Analysis
Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling a sustained downtrend.
Momentum: MACD histogram slightly positive (0.00323) but positively contracting—suggests weakening upside momentum rather than a fresh reversal.
RSI: RSI_6 ~21.9 indicates oversold conditions (bounce possible), but oversold alone is not a durable buy signal in a downtrend.
Levels: Pivot 1.312 (well above current price ~1.1508). Resistance: 1.472 / 1.572. Support: S1 1.152 (being tested) then S2 1.052.
Pattern-based forecast (similar candlesticks): ~70% chance of -0.3% next day, +3.39% next week, +8.68% next month—near-term drift weak, longer horizon bounce possible.
increases the odds of a short-term mean-reversion bounce.
Neutral/Negative Catalysts
No news in the past week—no clear event-driven catalyst to force a reversal.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 3.636M, down -67.83% YoY (sharp contraction).
Net income: -4.310M, down -2680.84% YoY (losses widened materially).
EPS: -1.65, down -16600.00% YoY (significant deterioration).
Overall: Latest-quarter growth trends are decisively negative, which weakens the case for buying dips purely on technical oversold readings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating trend or price target changes were provided in the data.
Wall Street-style pro view (inferred from available data): oversold setup could allow a tactical bounce.
Wall Street-style con view: steep YoY financial deterioration and bearish trend structure outweigh the oversold bounce thesis for an immediate buy.
Wall Street analysts forecast CWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CWD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CWD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
